TY - JOUR
T1 - Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis among Patients with Radiologically Isolated Syndrome
AU - Lebrun-Frénay, Christine
AU - Rollot, Fabien
AU - Mondot, Lydiane
AU - Zephir, Helene
AU - Louapre, Celine
AU - Le Page, Emmanuelle
AU - Durand-Dubief, Françoise
AU - Labauge, Pierre
AU - Bensa, Caroline
AU - Thouvenot, Eric
AU - Laplaud, David
AU - De Seze, Jerome
AU - Ciron, Jonathan
AU - Bourre, Bertrand
AU - Cabre, Philippe
AU - Casez, Olivier
AU - Ruet, Aurélie
AU - Mathey, Guillaume
AU - Berger, Eric
AU - Moreau, Thibault
AU - Al Khedr, Abdulatif
AU - Derache, Nathalie
AU - Clavelou, Pierre
AU - Guennoc, Anne Marie
AU - Créange, Alain
AU - Neau, Jean Philippe
AU - Tourbah, Ayman
AU - Camdessanché, Jean Philippe
AU - Maarouf, Adil
AU - Callier, Celine
AU - Vermersch, Patrick
AU - Kantarci, Orhun
AU - Siva, Aksel
AU - Azevedo, Christina
AU - Makhani, Naila
AU - Cohen, Mikael
AU - Pelletier, Daniel
AU - Okuda, Darin
AU - Vukusic, Sandra
N1 - Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Importance: Younger age, oligoclonal bands, and infratentorial and spinal cord lesions are factors associated with an increased 10-year risk of clinical conversion from radiologically isolated syndrome (RIS) to multiple sclerosis (MS). Whether disease-modifying therapy is beneficial for individuals with RIS is currently unknown. Objectives: To evaluate the 2-year risk of a clinical event (onset of clinical symptoms of MS) prospectively, identify factors associated with developing an early clinical event, and simulate the sample size needed for a phase III clinical trial of individuals with RIS meeting 2009 RIS criteria. Design, Setting, and Participants: This cohort study used data on prospectively followed-up individuals with RIS identified at 1 of 26 tertiary centers for MS care in France that collect data for the Observatoire Français de la Sclérose en Plaques database. Participants were aged 10 to 80 years with 2 or more magnetic resonance imaging (MRI) scans after study entry and an index scan after 2000. All diagnoses were validated by an expert group, whose review included a double centralized MRI reading. Data were analyzed from July 2020 to January 2021. Exposure: Diagnosis of RIS. Main Outcomes and Measures: Risk of clinical event and associated covariates at index scan were analyzed among all individuals with RIS. Time to the first clinical event was compared by covariates, and sample size estimates were modeled based on identified risk factors. Results: Among 372 individuals with RIS (mean [SD] age at index MRI scan, 38.6 [12.1] years), 354 individuals were included in the analysis (264 [74.6%] women). A clinical event was identified among 49 patients (13.8%) within 2 years, which was associated with an estimated risk of conversion of 19.2% (95% CI, 14.1%-24.0%). In multivariate analysis, age younger than 37 years (hazard ratio [HR], 4.04 [95% CI, 2.00-8.15]; P <.001), spinal cord lesions (HR, 5.11 [95% CI, 1.99-13.13]; P =.001), and gadolinium-enhancing lesions on index scan (HR, 2.09 [95% CI, 1.13-3.87]; P =.02) were independently associated with an increased risk of conversion to MS. Having 2 factors at the time of the index MRI scan was associated with a risk of 27.9% (95% CI, 13.5%-39.9%) of a seminal event within 2 years, increasing to 90.9% (95% CI, 41.1%-98.6%) for individuals with all 3 factors (3 risk factors vs none: HR, 23.34 [95% CI, 9.08-59.96]; P <.001). Overall, with 80% power to detect an effect size of 60% within 24 months, a total of 160 individuals with RIS were needed assuming an event rate of 20%. Conclusions and Relevance: This study found that age younger than age 37 years, spinal cord involvement, and gadolinium-enhancing lesions on index MRI scan were associated with earlier clinical disease and relevant to the number of enrolled patients needed to detect a potential treatment effect..
AB - Importance: Younger age, oligoclonal bands, and infratentorial and spinal cord lesions are factors associated with an increased 10-year risk of clinical conversion from radiologically isolated syndrome (RIS) to multiple sclerosis (MS). Whether disease-modifying therapy is beneficial for individuals with RIS is currently unknown. Objectives: To evaluate the 2-year risk of a clinical event (onset of clinical symptoms of MS) prospectively, identify factors associated with developing an early clinical event, and simulate the sample size needed for a phase III clinical trial of individuals with RIS meeting 2009 RIS criteria. Design, Setting, and Participants: This cohort study used data on prospectively followed-up individuals with RIS identified at 1 of 26 tertiary centers for MS care in France that collect data for the Observatoire Français de la Sclérose en Plaques database. Participants were aged 10 to 80 years with 2 or more magnetic resonance imaging (MRI) scans after study entry and an index scan after 2000. All diagnoses were validated by an expert group, whose review included a double centralized MRI reading. Data were analyzed from July 2020 to January 2021. Exposure: Diagnosis of RIS. Main Outcomes and Measures: Risk of clinical event and associated covariates at index scan were analyzed among all individuals with RIS. Time to the first clinical event was compared by covariates, and sample size estimates were modeled based on identified risk factors. Results: Among 372 individuals with RIS (mean [SD] age at index MRI scan, 38.6 [12.1] years), 354 individuals were included in the analysis (264 [74.6%] women). A clinical event was identified among 49 patients (13.8%) within 2 years, which was associated with an estimated risk of conversion of 19.2% (95% CI, 14.1%-24.0%). In multivariate analysis, age younger than 37 years (hazard ratio [HR], 4.04 [95% CI, 2.00-8.15]; P <.001), spinal cord lesions (HR, 5.11 [95% CI, 1.99-13.13]; P =.001), and gadolinium-enhancing lesions on index scan (HR, 2.09 [95% CI, 1.13-3.87]; P =.02) were independently associated with an increased risk of conversion to MS. Having 2 factors at the time of the index MRI scan was associated with a risk of 27.9% (95% CI, 13.5%-39.9%) of a seminal event within 2 years, increasing to 90.9% (95% CI, 41.1%-98.6%) for individuals with all 3 factors (3 risk factors vs none: HR, 23.34 [95% CI, 9.08-59.96]; P <.001). Overall, with 80% power to detect an effect size of 60% within 24 months, a total of 160 individuals with RIS were needed assuming an event rate of 20%. Conclusions and Relevance: This study found that age younger than age 37 years, spinal cord involvement, and gadolinium-enhancing lesions on index MRI scan were associated with earlier clinical disease and relevant to the number of enrolled patients needed to detect a potential treatment effect..
UR - http://www.scopus.com/inward/record.url?scp=85117792516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117792516&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2021.28271
DO - 10.1001/jamanetworkopen.2021.28271
M3 - Article
C2 - 34633424
AN - SCOPUS:85117792516
SN - 2574-3805
JO - JAMA Network Open
JF - JAMA Network Open
M1 - e2128271
ER -